INTRODUCTION {#s1}
============

The macrophage migration inhibitory factor (MIF) was one of the first cytokines to be described and has since been implicated in many diseases including infectious diseases and cancer \[[@R1]\]. D-Dopachrome tautomerase (DDT) shares 27 % sequence identity with MIF and X-ray analysis have revealed a highly conserved tertiary structure to MIF. However, the biological functions of D-DT have remained unclear for a long time \[[@R2], [@R3]\]. Recently, we and others have described functional overlaps between MIF and D-DT \[[@R4]-[@R6]\]. Both MIF and D-DT bind to the receptor CD74 and induce ERK1/2 phosphorylation, leading to macrophage migration arrest and counterregulation of glucocorticoid-induced immunosuppression \[[@R4]\]. In lung cancer cells, both MIF and D-DT contribute to CXCL8 and VEGF production, two important factors for tumor progression and angiogenesis \[[@R5]\]. Together with the finding that D-DT, as MIF, induces COX-2 expression through stabilization of β-catenin \[[@R6]\], these findings are strongly suggestive of a pro-tumorigenic role of D-DT, as previously demonstrated for MIF \[[@R7]\].

Analysis of clinical samples further showed that D-DT, like MIF, is elevated in sera of patients suffering from ovarian cancer and a correlation between D-DT levels and disease progression has been reported \[[@R4]\].

In cancer cells, MIF seem to play both an autocrine and paracrine role for tumor cell survival and invasiveness \[[@R8], [@R9]\]. In a MIF-null environment, tumor growth is significantly delayed and part of this effect is mediated by inefficient recruitment of pro-tumoral regulatory cell populations \[[@R7], [@R10]\]. The important role of MIF in tumor progression has led to the development of MIF-antagonizing or MIF-neutralizing strategies for the treatment of cancer. As a consequence, MIF-inhibitory small molecules and MIF-neutralizing antibodies are currently in preclinical development \[[@R10], [@R11]\].

Because MIF and D-DT have similar biological functions, we hypothesized that D-DT neutralizing therapeutic strategies may have a similar impact on tumor biology as demonstrated for MIF. We analyzed two aggressive murine tumor models for D-DT secretion in vitro and in vivo. We provide first evidence that mice are a suitable model for the analysis of D-DT in cancer. Furthermore, we demonstrate that the depletion of D-DT via siRNA or neutralization via antibodies results in reduced tumor growth. Therefore these strategies may be developed as a treatment modality against cancer.

RESULTS {#s2}
=======

D-DT is expressed and secreted by two murine cancer cell lines {#s2_1}
--------------------------------------------------------------

To address if D-DT could be used as a target in cancer models, we first analyzed if D-DT was produced by two murine cancer cell lines (the melanoma cell line B16F10 and the breast cancer cell line 4T1). D-DT expression in these cell lines was revealed by Western blot (Figure [1A](#F1){ref-type="fig"}). Both cell lines secrete significant amounts of D-DT in the cell supernatant as demonstrated by ELISA (Figure [1B](#F1){ref-type="fig"}). RT-PCR was performed to analyze the known receptors of MIF and D-DT for expression in B16F10 and 4T1 cells. CD74 (known receptor for both) and CXCR2 (known receptor for MIF) but not CXCR4 are expressed on both cell lines (Figure [1C](#F1){ref-type="fig"}). To further confirm the significance of our findings, we next investigated for the presence of D-DT in tumor bearing mice. Serum was taken from mice with established tumors and D-DT concentration was measured by ELISA. B16F10 tumor bearing mice (n = 22) and 4T1 tumor bearing mice (n = 10) had higher serum levels of D-DT in comparison to wild-type litter mates (n = 26 and 9, respectively). These data indicate a possible autocrine and paracrine role of D-DT in the investigated cancer models.

![Expression and secretion of D-DT in two murine cancer cell lines\
(A): Western blot analysis of D-DT levels in B16F10 and 4T1 tumor cells. 50 µg of protein lysate were loaded per lane, β-actin served as a loading control. Results are representative of three independent experiments. (B): D-DT secretion by B16F10 and 4T1 cells. 10^6^ tumor cells were seeded. Supernatants were removed after 24 h and D-DT levels analyzed by ELISA. Results are representative of three independent experiments. Arrows represent the standard error of the mean. (C): Quantitative PCR or known MIF receptors. CD74, CXCR2 and CXCR4 expression was analyzed. β-Actin served as loading control, water and splenocytes served as negative and positive control, respectively. Results are representative of three independent experiments. (D): Serum levels of D-DT in B16F10 and 4T1 tumor-bearing mice. B16F10 tumor bearing mice (n = 22) and matched C57Bl/6 control mice (n = 26) were bled fourteen days after tumor induction. 4T1 tumor bearing mice (n = 10) and matched Balb/c control mice (n = 9) were bled twenty one days after tumor induction. Serum was analyzed by ELISA](oncotarget-05-0103-f001){#F1}

D-DT silencing reduces proliferative capacity of murine melanoma cells {#s2_2}
----------------------------------------------------------------------

MIF mediates cell proliferation and protects tumor cells from apoptosis \[[@R9], [@R11]\]. We thus hypothesized a similar role for D-DT, which would qualify D-DT as a therapeutic target. We designed specific siRNA against D-DT which mediated a significant knock-down of D-DT on the protein level in B16F10 cells (Figure [2A](#F2){ref-type="fig"}). Importantly, no impact on MIF expression could be observed (data not shown). Knock-down of D-DT resulted in a significant decrease in cell proliferation compared to a decoy siRNA (Figure [2B](#F2){ref-type="fig"}). This decrease in cell proliferation was not due to a reduced cell viability or an increase in cell death (data not shown). Next, we induced apoptosis in B16F10 cells by treating with staurosporin after D-DT silencing. After depletion of D-DT, we observed an increase of apoptosis in comparison to control groups (Figure [2C](#F2){ref-type="fig"}).

![Effects of D-DT knock-down or neutralization on B16F10 tumor cells\
(A): Analysis of protein depletion after siRNA transfection by Western blot. Transfection was performed twice 48 h apart. Untransfected, control siRNA-transfected and D-DT siRNA-transfected B16F10 tumor cells were analyzed by Western blot 24 h after the last transfection. Results are representative of three independent experiments. (B): Analysis of proliferation by BrdU assay. siRNA for D-DT or control were transfected as in (A) and cells were incubated 48 h after the second transfection for 4 h with BrdU. Proliferation of untreated, control siRNA and D-DT siRNA treated cells were compared. Results are representative of three independent experiments. Arrows represent the standard error of the mean. (C): Apoptosis induction after siRNA transfection through 2 µM staurosporin. Cells were transfected two times, 48 h apart. 24 h after the second transfection, cells were seeded, rested for another 24 h and treated with Staurosporin. Annexin V and PI staining is performed to compare control siRNA and D-DT siRNA-treated B16F10 tumor cells 24 h after staurosporin treatment. Results are representative of three independent experiments. (D): Growth of B16F10 tumors treated with anti-D-DT antibody or control antibody. 250 µg of antibody was administered i.p. every second day (n = 4 per group). Results are representative of two independent experiments. Arrows represent standard error of the mean.](oncotarget-05-0103-f002){#F2}

D-DT neutralization slows tumor progression in vivo {#s2_3}
---------------------------------------------------

Finally, we tested if D-DT neutralization impacts on tumor growth in vivo. We purified polyclonal D-DT antibodies from immunized rabbit serum by affinity chromatography using the recombinant antigen. Affinity-purified D-DT antibodies or polyclonal rabbit IgG were administered at a dose of 250 µg per mice every second day from tumor injection (n = 4 mice per group). While anti-D-DT antibody injections only resulted in a trend towards longer survival (median survival 23 days for the anti-D-DT-treated group, 18.5 days for the IgG-treated group, results pooled from two experiments; p not significant), treatment significantly slowed tumor progression (Figure [2D](#F2){ref-type="fig"}).

DISCUSSION {#s3}
==========

This report is the first to show expression and secretion of D-DT in the B16F10 melanoma and 4T1 breast cancer model. We also show for the first time that D-DT has a proliferative and anti-apoptotic effect on B16F10 melanoma cells and that targeting of D-DT through siRNA or polyclonal D-DT antibodies may slow tumor progression in this model.

MIF expression has been demonstrated in a wide variety of tumors \[[@R1]\]. In contrast, D-DT expression so far has been evaluated in healthy tissues and only a few cancer models such as lung and colon cancer. In these cell lines a similar expression pattern as MIF has been observed \[[@R2], [@R4]\]. Therefore, it was not surprising that D-DT is expressed and secreted in the melanoma cell line B16F10 and in the breast cancer cell line 4T1. However, we observed differences between in vitro and in vivo D-DT production: in vitro, D-DT secretion is higher in B16F10 cells, as opposed to in vivo where D-DT serum levels were higher in mice bearing 4T1 tumors. One possible explanation for this discrepancy may be an additional cellular source of D-DT induced by the growing tumors. In fact, immune cells such as myeloid cells are an established source of MIF and D-DT production. These cells play an important role in the biology of these tumor models \[[@R12]\]. The 4T1 tumor model induces a heavy expansion of the myeloid compartment leading to marked splenomegaly and to strong myeloid infiltrates at the tumor sites, both of which may account for the increased D-DT serum levels \[[@R12]\].

Due to the overlapping biological functions of MIF and D-DT, we hypothesized that D-DT may have proliferative and anti-apoptotic effects. The in vitro and in vivo findings confirmed this hypothesis. The findings have important implications, since they constitute the first step in evaluating D-DT as a potential therapeutic target for cancer therapy. Due to the wide spectrum of expression of D-DT in many cancer types analyzed so far, targeting of D-DT may form an attractive option.

In summary, we demonstrate that D-DT may be a suitable target for cancer therapy \[[@R11]\]. Possible formats would be systemic administration of siRNA or monoclonal neutralizing D-DT antibodies, both of which need to be established. It will be interesting to know if our observations in a murine system will also translate in human cancer models and thus warrant further preclinical analysis of D-DT as a therapeutic target.

MATERIALS AND METHODS {#s4}
=====================

Cell lines {#s4_1}
----------

The murine melanoma cell line B16F10 was cultured in DMEM with 10% fetal bovine serum (FBS, Life Technologies, USA), 1% penicillin and streptomycin (PS) and 1% L-glutamine (all from PAA, Germany). The murine breast cancer cell line 4T1 was provided by M. Wartenberg (Jena, Germany) and cultured in RPMI 1640 with 10% FBS, 1% PS and 1% L-glutamine.

Animal experiments {#s4_2}
------------------

Wild type C57BL/6RJ and Balb/cJ mice were purchased from Janvier (St. Berthevin, France). B16F10 and 4T1 tumors were induced by injecting 5 x 105 or 106 tumor cells per mice, respectively. 250 µg of affinity-purified polyclonal rabbit D-DT antibody or polyclonal rabbit IgG were injected i.p. every second day. All animal studies were approved by the local regulatory agency (Regierung von Oberbayern).

D-DT ELISA {#s4_3}
----------

D-DT ELISA was constructed with in-house antibodies and was performed as described \[[@R4]\]. In brief, recombinant D-DT was sent to the SEQLAB-Sequence laboratories (Göttingen, Germany) where it was used to immunize rabbits. Anti D-DT rabbit serum antibodies were recovered using affinity chromatography with binding to recombinant D-DT bound on HiTrap-NHS columns (GE Healthcare, Freiburg, Germany), were eluted and thereafter dialyzed against PBS.

Western blot {#s4_4}
------------

Polyclonal rabbit D-DT antibody was generated and used for Western blot as described \[[@R4], [@R13]\].

Reverse transcriptase polymerase chain reaction {#s4_5}
-----------------------------------------------

Reverse transcription and polymerase chain reaction was performed as described \[[@R13]\] using the following primer sequences: CD74-fwd: 5\'-GCA GTG GCT CTT GTT TGA GA-3\', CD74-rev: 5\'-TTC CTG GCA CTT GGT CAG TA-3\', CXCR2-fwd: 2 5\'-CAG GAC CAG GAA TGG GAG TA-3\', CXCR2-rev: 5\'-TCC CCT CCA AAT ATC CCC TA-3\', CXCR4-fwd: 5\'-TGG AAC CGA TCA GTG TGA GT-3\', CXCR4-rev: 5\'-GGG CAG GAA GAT CCT ATT GA-3\', β-Actin-fwd: 5\'-CTA AGG CCA ACC GTG AAA AG-3\', β-Actin-rev: 5\'-ACC AGA GGC ATA CAG GGA CA-3\'

siRNA lipofection and proliferation assay {#s4_6}
-----------------------------------------

siRNA lipofection was performed as described \[[@R14]\] with the following siRNA pairs: D-DT-sense 5\'-CUU GGC AGA UCG GAA AG-3\' and D-DT-antisense 5\'-UUC UUU CCG AUC UGC CAA G-3\'. A decoy siRNA served as control: 5\'-GCG CAU UCC AGC UUA CGU A-3\'. BrdU-proliferation assay (Roche, Mannheim, Germany) was performed according to the manufacturer\'s instructions.

Apoptosis assay by annexin V-propidium iodide staining {#s4_7}
------------------------------------------------------

Analysis of apoptosis was performed as described \[[@R13]\]. Staurosporin (Sigma, Munich Germany) was used as indicated.

Statistics and data analysis {#s4_8}
----------------------------

For statistics GraphPad Prism software, version 5.0b was used. All t-tests were two-tailed and p-values \< 0.05 were considered significant. Differences between experimental conditions were analyzed using the unpaired Student\'s t-test. For in vivo experiments, differences between groups were analyzed using two-way ANOVA with correction for multiple testing.
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